Last reviewed · How we verify

Cromoglycate

Vishwajit Nimgaonkar, MD PhD · Phase 3 active Small molecule ✓ Verified May 2026

Cromoglycate is a Small molecule drug developed by Vishwajit Nimgaonkar, MD PhD. It is currently in Phase 3 development for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis. Also known as: NasalCrom, DNCG Iso, Lomudal.

Cromoglycate is a small molecule drug, classified as a mast cell stabilizer, which prevents the release of inflammatory chemicals such as histamine from mast cells. It has been studied in various clinical trials for conditions including pediatric asthma, rhinitis, and allergic reactions, as well as Alzheimer's disease and acute stroke.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCromoglycate
Also known asNasalCrom, DNCG Iso, Lomudal
SponsorVishwajit Nimgaonkar, MD PhD
TargetProtein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
ModalitySmall molecule
Therapeutic areaMetabolic
PhasePhase 3

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cromoglycate

What is Cromoglycate?

Cromoglycate is a Small molecule drug developed by Vishwajit Nimgaonkar, MD PhD, indicated for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis.

What is Cromoglycate used for?

Cromoglycate is indicated for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis, Asthma, Asthma management.

Who makes Cromoglycate?

Cromoglycate is developed by Vishwajit Nimgaonkar, MD PhD (see full Vishwajit Nimgaonkar, MD PhD pipeline at /company/vishwajit-nimgaonkar-md-phd).

Is Cromoglycate also known as anything else?

Cromoglycate is also known as NasalCrom, DNCG Iso, Lomudal.

What development phase is Cromoglycate in?

Cromoglycate is in Phase 3.

What does Cromoglycate target?

Cromoglycate targets Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing